Albert Bourla

About Albert Bourla

As Chairman and Chief Executive Officer, Albert Bourla leads Pfizer in its purpose, “Breakthroughs that change patients’ lives,” with a focus on driving the scientific and commercial innovation needed to transform human health. Under Albert’s leadership, Pfizer is boldly pursuing one of the most ambitious strategies in the biopharmaceutical industry, aiming to redefine what is possible across oncology, internal medicine, inflammation and immunology and vaccines. Pfizer is at the forefront of reshaping cancer care. With the 2023 acquisition of Seagen, the company continues to advance a robust pipeline poised to deliver multiple breakthroughs by 2030. Pfizer is also building a meaningful presence in obesity and metabolic disease with a highly differentiated portfolio of next-generation treatments following the 2025 acquisition of Metsera. Albert has made artificial intelligence central to how Pfizer discovers, develops and manufactures medicines, believing it will accelerate innovation. Albert became CEO in January 2019 and advanced Pfizer’s transformation into a science-driven company, divesting non-science-based businesses and increasing investment in R&D and technology. He and his leadership team established Pfizer’s Purpose Blueprint, built on four values: Courage, Excellence, Equity and Joy. The urgency and innovation that defined Pfizer’s response to COVID-19 — delivering a safe and effective vaccine in eight months and the first FDA-authorized oral antiviral treatment — now shape how the company works across its entire portfolio. Born in Thessaloniki, Greece, to a family of Holocaust survivors, Albert is a Doctor of Veterinary Medicine with a Ph.D. in the Biotechnology of Reproduction from the Veterinary School of Aristotle University. During more than 30 years at Pfizer, he held senior positions in five countries before becoming CEO. Albert is a Genesis Prize Laureate. He has received the American Association for Cancer Research (AACR) Outstanding Achievement Award for Service to Cancer Science and Medicine, the Anti-Defamation League (ADL) Courage Against Hate Award and the Concordia Leadership Award. He was named among Fortune’s Most Powerful People in Business, Time’s 100 Most Influential People in Health and CEO of the Year by CNN Business. He is Chair of the Pfizer Foundation and Co-Chair of the Partnership for New York City. He previously served as Chair of the Pharmaceutical Research and Manufacturers of America (PhRMA) and as President of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).

Experience

1. Chief Executive Officer

   Pfizer

   Jan 2019 — Present · New York, NY, US

   I am the Chief Executive Officer (CEO) of Pfizer, one of the world\'s premier innovative biopharmaceutical companies. In my previous role, I was Chief Operating Officer overseeing the company\'s commercial, strategy, manufacturing and global product development functions.

Education

• Aristoteleion Panepistimion Thessalonikis

  Doctor of Philosophy (Ph.D.)

• Aristotle University of Thessaloniki (AUTH)

  DVM

  1979 — 1985

Skills

• Sales Effectiveness
• Drug Development
• Immunology
• Biopharmaceuticals
• Market Access
• Licensing
• Commercialization
• Regulatory Affairs
• Emerging Markets
• Market Analysis
• Strategy Development
• Business Development
• R&D
• Pharmaceuticals
• Pharmaceutical Sales
• Vaccines
• Life Sciences
• Strategic Planning
• Strategy
• Pharmaceutical Industry
• Veterinary Medicine
• New Business Development
• Biotechnology
• Medical Devices
• Cross-Functional Team Leadership
• Oncology
• Animal Health
• Product Launch
• Pharmaceutics
• Leadership
• Clinical Trials
• Clinical Development